ArticleCureus2025
Piperacillin-Tazobactam-Induced Generalized Exanthematous Pustulosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Piperacillin/Tazobactam-Induced Bilateral Optic Disc Edema With Serous Retinal Fluid in a Young Female With Pelvic Abscess and Sepsis.Case reports in infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute generalized exanthematous pustulosis (AGEP) is an extremely rare condition that is mostly caused by antibiotic exposure. Clinically, it manifests as the rapid appearance of multiple sterile pustules, swelling, and erythema within a few hours to days of exposure to the offending medication. Skin lesions usually resolve by desquamation after discontinuation of the offending agent. We present a case of a 58-year-old female patient with AGEP in the setting of piperacillin-tazobactam use, which was confirmed by histopathology with findings of neutrophilic pustules and eosinophilic infiltration. Her symptoms started resolving within three days of stopping the medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.